Swiss Software Stock News

SWX:GEBN
SWX:GEBNBuilding

Geberit (SWX:GEBN) Could Be Fully Valued As 5% To 6% Growth Guidance Lands

Geberit (SWX:GEBN) is back in focus after the company paired its half year 2026 results with fresh guidance pointing to 5% to 6% net sales growth in local currencies for the full year. See our latest analysis for Geberit. For investors tracking the bigger picture, Geberit’s 1 month share price return of 12.76% and 3 month return of 14.64% indicate building momentum, even though the year to date share price return is down 5.91% and the 1 year total shareholder return is down 2.15%, while the 3...
SWX:SFZN
SWX:SFZNLife Sciences

Siegfried Holding (SWX:SFZN) Stock Eyes Margin Gains Against Rich Valuation

Siegfried Holding stock went into this earnings print with a solid recent run, up about 13.5% over the past month and trading at CHF80.25, well above a discounted cash flow estimate of CHF59.01. The headline today is not a surprise beat or miss. It is a margin story. The company delivered a core EBITDA margin of 22.4% in the first half with management talking up further improvement above 23% for the full year. That mix of strong recent share gains, a richer price tag and quietly firming...
SWX:PSPN
SWX:PSPNReal Estate

PSP Swiss Property (SWX:PSPN) Could Be 82% Overvalued Following Strong Earnings

Why PSP Swiss Property’s latest earnings matter for investors PSP Swiss Property (SWX:PSPN) recently reported second quarter and half year 2026 earnings, highlighting higher net income and basic earnings per share while sales stayed broadly unchanged. This earnings profile is attracting fresh investor attention. See our latest analysis for PSP Swiss Property. Following the earnings announcement on 18 August 2026, PSP Swiss Property’s share price at CHF145.50 reflects a modest year to date...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is Novartis (SWX:NOVN) Fully Valued On Its 2026 ESC Congress Data Plans?

Why the 2026 ESC Congress Matters for Novartis Stock Novartis (SWX:NOVN) is back in focus after confirming plans to present data from 10 cardiovascular studies at the 2026 European Society of Cardiology Congress, including late breaking Leqvio and abelacimab results. See our latest analysis for Novartis. At a share price of CHF127.42, Novartis has shown firm momentum, with a 7 day share price return of 4.07%, a year to date share price return of 17.44%, and a 5 year total shareholder return...
SWX:BAER
SWX:BAERCapital Markets

Julius Bär Stock And Other European Safe Haven Financials In Focus

With investors questioning the reliability of US Treasuries and the dollar at the same time, attention is drifting toward markets that feel calmer and more predictable. That shift can create openings and risks in stocks linked to Swiss and other safe haven currencies, as clients reconsider where they hold their cash and portfolios. This article walks through three stocks exposed to that story and explains how the current backdrop could matter for each one. The sample of stocks covered below...
SWX:VZN
SWX:VZNCapital Markets

VZ Holding (SWX:VZN) Faces A 22% Above Fair Value Gap On Half Year Earnings

VZ Holding (SWX:VZN) is back in focus after reporting half year 2026 earnings on 14 August. Net income reached CHF 131.69 million, with basic earnings per share from continuing operations at CHF 3.34. See our latest analysis for VZ Holding. The earnings release appears to have supported momentum in VZ Holding’s share price, with a 30 day share price return of 8.68% and a 90 day share price return of 18.54%. Over a longer period, the 5 year total shareholder return of 120.71% contrasts with a...
SWX:TEMN
SWX:TEMNSoftware

Temenos (SWX:TEMN) Could Be 7% Undervalued As CHF 100 Million Buyback Starts

Temenos (SWX:TEMN) has announced a share repurchase program of up to CHF 100 million, authorized by its Board on 12 August 2026 and running until late February 2027, primarily for general corporate uses. See our latest analysis for Temenos. At a latest share price of CHF 74.40, Temenos has seen a 30 day share price return of 11.54% and a 1 year total shareholder return of 5.84%, while the 5 year total shareholder return remains down 43.41%. This suggests that recent momentum has improved from...
SWX:SDZ
SWX:SDZPharmaceuticals

Sandoz Group (SWX:SDZ) Looks Fully Valued After Henlius Biosimilar Deal

Sandoz Group (SWX:SDZ) is back in focus after the company agreed a collaboration with Shanghai Henlius Biotech to develop, manufacture and commercialise up to 10 biosimilars, with milestone payments up to US$322 million. See our latest analysis for Sandoz Group. The collaboration news arrives as Sandoz Group trades at CHF73.84, with a 30 day share price return of 15.45% and a year to date share price return of 29.05%. Over the past year, total shareholder return of 48.82% indicates that...
SWX:SENS
SWX:SENSElectronic

Sensirion Holding (SWX:SENS) Stock Grapples With FX Drag Despite Profit Jump

Sensirion Holding shares closed at CHF78.90 on Friday after a choppy week that left the stock slightly lower over seven days but modestly higher over the past month. The market reaction feels cautious. The headline from these H1 numbers is clear. Profitability in the sensor business is tightening under the microscope. Revenue for the first half came in at CHF179.0m while basic earnings per share reached CHF1.21. The key development is in the trailing picture. Net profit margin on the last...
SWX:ROP
SWX:ROPPharmaceuticals

Roche (SWX:ROP) Stock Looks Undervalued As US Manufacturing Expansion Continues

Roche Holding stock has delivered a 60.7% return over the past three years, and the recent run raises the question of whether the current price still lines up with what the valuation checks suggest. Over the past 3 years, Roche Holding has returned 60.7%, which puts recent gains front and centre in any assessment of what investors are now paying for the stock. Large ongoing investments in U.S. manufacturing capacity and diagnostics partnerships can support future cash generation. However,...
SWX:SIGN
SWX:SIGNPackaging

Is SIG Group’s (SWX:SIGN) CEO Shift Quietly Redefining Its Aseptic Systems Investment Story?

SIG Group AG recently appointed Ann-Kristin Erkens as CEO, replacing Mikko Keto, as its transformation programme delivered higher adjusted EBIT margins and stronger free cash flow, while the company reiterated its 2026 outlook and focus on aseptic system solutions. The planned Capital Markets Day in October, where SIG will outline its updated strategy and mid-term targets, gives investors a clearer lens on how the transformation programme could influence future business priorities and...
SWX:DKSH
SWX:DKSHTrade Distributors

Why DKSH Holding (SWX:DKSH) Is Back In The Spotlight

DKSH Holding (SWX:DKSH) is back in focus after its Malaysian unit reported a 34.8% year-on-year jump in second quarter net profit, supported by higher revenue and unrealised foreign exchange gains. See our latest analysis for DKSH Holding. At a share price of CHF66.40, DKSH Holding has seen its 30 day share price return of 3.75% and year to date share price return of 13.31%. The 1 year total shareholder return is 19.71%, which suggests momentum has been building rather than fading...
SWX:SIKA
SWX:SIKAChemicals

Sika (SWX:SIKA) Could Be 6% Undervalued Following Hybrid Bond Issue And Stable Outlook

Sika (SWX:SIKA) has drawn fresh investor attention after issuing €1b in hybrid capital bonds split into two callable, subordinated tranches, while S&P shifted its issuer rating outlook on the company from Negative to Stable. See our latest analysis for Sika. For investors, the hybrid bond issuance and S&P outlook revision arrive as Sika’s share price shows renewed momentum, with a 30-day share price return of 17.92% and a 90-day gain of 25.14%, even though the 5-year total shareholder return...
SWX:EFGN
SWX:EFGNCapital Markets

3 Retail And Wealth Bank Stocks For Investors Rethinking Barclays```

Barclays is once again reshaping its investment bank, cutting leadership, tightening capital and leaning harder on its markets division. That shift could leave more room for UK and European retail and wealth focused banks that rely on simpler deposit and lending models rather than capital intensive trading and dealmaking. This article walks through three stocks exposed to that story and explains how the recent shake up might matter for your portfolio decisions. The three stocks covered below...
SWX:SCHN
SWX:SCHNMachinery

Schindler Holding (SWX:SCHN), What Is Behind The Fresh Attention?

Schindler Holding wins high profile New York modernization contract Schindler Holding (SWX:SCHN) has secured the modernization of 31 elevators at the General Motors Building in Midtown Manhattan, a high profile project that features its PORT destination system in a heavily trafficked office tower. See our latest analysis for Schindler Holding. The GM Building contract comes at a time when Schindler Holding’s share price has shown a 3.69% gain over the past month, while its year-to-date share...
SWX:GALE
SWX:GALEHealthcare

Should Galenica’s Softer 2026 Half-Year Profit but Reaffirmed Guidance Require Action From Galenica (SWX:GALE) Investors?

Galenica AG recently reported past half-year 2026 results, with sales rising to CHF 2,136.45 million and revenue to CHF 2,143.28 million, while net income decreased to CHF 66.35 million and earnings per share eased compared with the prior year period. Despite the softer profitability, management confirmed its 2026 outlook for consolidated net sales growth of 5.7% and EBIT growth between 6% and 8%, underscoring confidence in the business trajectory. With Galenica confirming its 2026 earnings...
SWX:SUNN
SWX:SUNNTelecom

Sunrise Communications (SWX:SUNN) Stock Faces Dividend Strain As Revenue Slips

Sunrise Communications stock came into today looking bruised, with the share price drifting down roughly 3% over the past month and about 3% over the last quarter. The long term pitch around a cheap telecom with a turnaround story met some hard numbers in the latest release. Revenue for the last twelve months sat at CHF 2.98b while the company still reported a loss from continuing operations and negative earnings per share. The real headline is not growth but pressure. Profitability remains...
SWX:DOCM
SWX:DOCMConsumer Retailing

DocMorris (SWX:DOCM) Stock Faces Loss Pressure As Revenue Expands

DocMorris stock closed at CHF10.00 on the day of its latest earnings, capping a volatile few months that included a sharp rebound over the past quarter. The market has been treating DocMorris as a high growth, online pharmacy bet. The headline from the latest numbers is more sobering. Revenue over the last twelve months reached about CHF1.1b, yet the company still reported a sizeable loss from continuing operations and a loss per share in the mid single digit CHF range. The expectation gap is...
SWX:STMN
SWX:STMNMedical Equipment

Straumann Holding (SWX:STMN) Stock Rich Valuation Meets Profit Margin Compression

Straumann Holding stock closed at CHF97.22 on the day its latest figures landed, well below an internal discounted cash flow estimate of CHF160.06. The market has been trimming exposure in recent weeks; yet the fresh numbers highlight a different story. Earnings sit on a compressed 13.7% net profit margin after a CHF136.0m one off loss in the last twelve months, while the P/E of 43.5x prices Straumann as a premium dental equipment play. The key question for you is whether that margin squeeze...
SWX:SIGN
SWX:SIGNPackaging

SIG Group (SWX:SIGN) Could Be 13% Below Fair Value Following CEO Shake Up

SIG Group (SWX:SIGN) abruptly replaced CEO Mikko Keto with former CFO Ann-Kristin Erkens less than six months into Keto’s tenure, raising questions about leadership stability despite reaffirmed guidance and an upcoming Capital Markets Day. See our latest analysis for SIG Group. For context, SIG Group’s 1 day share price return of 1.31% comes after a sharp 7 day share price decline of 14.20%. The 90 day share price return of 11.99% and year to date share price return of 14.92% contrast with a...